Table 138Evidence summary table: haloperidol versus quetiapine – specific adverse events

OutcomeStudiesParticipantsEffect EstimateI2Less with
Behavior and psychosis
Agitation46,68,115,12349840.83 (0.51, 1.36)0%ND
Anxiety6814481.86 (0.92, 3.76)NEND
Asthenia6814480.29 (0.12, 0.71)NEhaloperidol
Depression11512012.75 (0.75, 10.06)NEND
Deterioration731123NENEND
Fatigue1231250.36 (0.02, 8.05)NEND
Irritability1231253.23 (0.14, 72.46)NEND
BMI and weight
Overweight9112070.65 (0.37, 1.14)NEND
Weight gain46,91,12335420.59 (0.39, 0.89)0%haloperidol
Cardiovascular
ECG abnormalities46,9125170.50 (0.05, 5.48)NEND
Orthostatic hypotension46,68,11539590.49 (0.25, 0.94)0%haloperidol
Cholinergic and anticholinergic
Dry mouth68,115,12336740.32 (0.15, 0.65)0%haloperidol
Hypersalivation68,12324731.88 (0.22, 16.18)50%ND
CNS
Dizziness46,6827580.68 (0.36, 1.28)0%ND
Drowsiness1231250.36 (0.02, 8.05)NEND
Sedation1231253.23 (0.14, 72.46)NEND
Somnolence46,68,115,12349840.57 (0.39, 0.84)0%haloperidol
Dermatology
Dry skin/rash1231253.23 (0.14, 72.46)NEND
Endocrine (prolactin - thyroid)
Amenorrhea/Menstrual cycle irregularities1231250.36 (0.02, 8.05)NEND
Cold flashes1231250.36 (0.02, 8.05)NEND
Galactorrhea471355.28 (0.27, 102.58)NEND
Hyperprolactinemia68,79,9139432.24 (1.04, 4.80)89%quetiapine
Thyroid function test abnormalities6814480.05 (0.00, 0.79)NEhaloperidol
EPS
Akathisia46,68,79,91,115514543.51 (1.84, 6.72)68%quetiapine
Akinesia6814482.92 (0.12, 71.32)NEND
Cogwheel rigidity6814482.92 (0.12, 71.32)NEND
Dyskinesia9112075.05 (0.25, 103.88)NEND
Dystonia46,68,9139653.94 (0.79, 19.70)29%ND
EPS46,68,79,80,11551292NR90%ND
Fine tremors1231250.36 (0.02, 8.05)NEND
Hypertonia68,7927362.05 (0.82, 5.10)60%ND
Involuntary movement (jaw)1231250.36 (0.02, 8.05)NEND
Neck rigidity6814482.92 (0.12, 71.32)NEND
Oculogyric crisis6814486.82 (0.35, 131.19)NEND
Parkinsonism46,9125174.04 (1.97, 8.26)53%quetiapine
Stiffness1231253.23 (0.14, 72.46)NEND
Tardive dyskinesia65135NENEND
Tremor68,11526493.80 (2.12, 6.81)0%quetiapine
Twitch in the extremities1231250.36 (0.02, 8.05)NEND
GI
Constipation46,6827580.45 (0.22, 0.93)0%haloperidol
Dyspepsia4613100.99 (0.35, 2.78)NEND
Hematology
Agranulocytosis461310NENEND
Leucopenia6814480.32 (0.03, 3.10)NEND
Hepato-biliary
Elevated liver transaminases6814480.14 (0.02, 1.12)NEND
Metabolic
HDL (low)9112070.76 (0.27, 2.11)NEND
Hypercholesterolemia9112071.24 (0.63, 2.45)NEND
Hyperglycemia9112070.67 (0.25, 1.82)NEND
Hypertriglyceridemia9112071.19 (0.56, 2.54)NEND
Ophthalmology
Blurred vision1231253.23 (0.14, 72.46)NEND
Sleep
Insomnia46,68,115,12349841.12 (0.71, 1.76)29%ND
Systemic AE
Headache46,68,115,12349841.31 (0.86, 1.98)5%ND

Significant results are in bold; AE = adverse event; BMI = body mass index; CNS = central nervous system; ECG = electrocardiogram; EPS = extrapyramidal symptoms/syndrome; GI = gastrointestinal; HDL = high density lipoprotein; I2 = I–squared; ND = no difference; NE = not estimable

From: Appendix N, Summary Tables of Adverse Events

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 63.
Abou-Setta AM, Mousavi SS, Spooner C, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.